Health economic assessment of Kyprolis in combination with Revlimid and dexamethasone

17 December 2019 - TLV has developed a new health economic knowledge base for the regions of the drug Kyprolis ...

Read more →

Zejula is included in the high-cost protection with limitation

25 November 2019 - Zejula (niraparib) is included in the high-cost, limited-subsidy protection from December 1, 2019.  ...

Read more →

Health economic assessment of Tecentriq for triple negative breast cancer

8 November 2019 - TLV has produced a health economic knowledge base for the county council for the drug Tecentriq (atezolizumab).  ...

Read more →

Joint evaluation report of sotagliflozin (Zynquista)

28 June 2019 - TLV, together with the corresponding authorities in the Netherlands, ZIN, and in Ireland, NCPE, have written ...

Read more →

Health economic assessment of Kymriah in diffuse large B-cell lymphoma

20 June 2019 - TLV has produced a health economic knowledge base for county councils for CAR-T cell treatment Kymriah ...

Read more →

TLV does not extend Hemlibra's current subsidy

18 June 2019 - Hemlibra has been included in the high-cost protection since autumn 2018 for the treatment of patients ...

Read more →

TLV publishes first joint report within the FINOSE co-operation

11 June 2019 - FINOSE is a collaboration between the HTA authorities, the pharmaceutical company Fimea (Finland), the Norwegian Medicines Agency, ...

Read more →

Health economic assessment of Luxturna in the treatment of visual impairment caused by hereditary eye disease

29 May 2019 - TLV has produced a health economic knowledge base for the region for the drug Luxturna (voretigene ...

Read more →

Health economic assessment of Tegsedi in hereditary transthyretin amyloidosis

17 May 2019 - TLV has produced a health economic knowledge base for the regions for Tegsedi (inotersen) that treat hereditary ...

Read more →